Iovance Biotherapeutics (IOVA)
(Real Time Quote from BATS)
$8.23 USD
+0.27 (3.39%)
Updated Jul 22, 2024 03:05 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IOVA 8.23 +0.27(3.39%)
Will IOVA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IOVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IOVA
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
IOVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Other News for IOVA
How Is The Market Feeling About Iovance Biotherapeutics?
Interesting IOVA Put And Call Options For March 2025
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics put volume heavy and directionally bearish
7 ‘Death Cross’ Stocks That Could Be Contrarian Buys